Michelle Dawson posts

Post published on Twitter/X on 12 Jan 2022 04:46

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms
Open original post

Information about the link integrated into the post

Clinical trial

Icahn School of Medicine at Mount Sinai, National Institute of Neurological Disorders and Stroke (NINDS) (2022). A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism. ClinicalTrials.gov. Icahn School of Medicine at Mount Sinai.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Icahn School of Medicine at Mount Sinai, National Institute of Neurological Disorders and Stroke (NINDS) (2022). A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism. ClinicalTrials.gov. Icahn School of Medicine at Mount Sinai.

Publication date
19 Jan 2022
Identifier
NCT05187377
Authors
Icahn School of Medicine at Mount Sinai, National Institute of Neurological Disorders and Stroke (NINDS)
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Icahn School of Medicine at Mount Sinai
Metadata source
clinicaltrials.gov

Abstract

This clinical trial will use growth hormone as a novel treatment for Phelan-McDermid syndrome (PMS) and idiopathic autism. A double-blind, placebo-controlled crossover trial design will be used in 30 children with idiopathic autism and 15 children with PMS to evaluate the the effects of growth hormone on visual evoked potentials (VEPs), socialization, language, and repetitive behaviors. The researchers expect to provide evidence for the feasibility of using VEPs in PMS, and to show support for growth hormone in ameliorating clinical symptoms of ASD.

Open source Link to cited source